Middle East & Africa Bladder Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Cancer Type, Diagnostics and Therapeutics and Geography

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 5.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The bladder cancer therapeutics and diagnostics market will witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing innovation in drug development. Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. In countries in the Middle East and Africa (MEA) region like the United Arab Emirates (UAE), the bladder cancer is 8th most common type of cancer, as per Globocan 2018 data.

In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Middle East and Africa. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.

Hence, the increasing awareness about bladder cancer and related therapies, the Middle East and Africa bladder cancer therapeutics and diagnostics market is expected to grow in the coming future. 

Scope of the report

As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market.

By Cancer Type
Transitional Cell Bladder Cancer
Superficial Bladder Cancer
Invasive Bladder Cancer
Other Rare Types
By Diagnostics and Therapeutics
By Therapeutics
Chemotherapy
Immunotherapy
Radiation Therapy
Surgery
By Diagnostics
Cytoscopy
Biopsy
Urinalysis
Others
Geography
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

Radiation Therapy is Expected to Cover a Large Share of the Market

Bladder cancer is highly prevalent diseases and it increases with age. As per a 2018 Globocan report, the bladder cancer incidence in the Middle East and Africa region is expected to increase in the future. The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also, offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Advancements in radiation therapy and expected increase in number of bladder cancer patients is expected to help the growth of this market.

Graph.png

Competitive Landscape

Most of the global players are present in the Gulf Cooperation Council (GCC) region of the Middle East and Africa (MEA) owing to factors such as economic growth in the last few decades.

The Africa region consists of some developing and underdeveloped countries. The healthcare systems in these countries are still not well structured and stable, due to the lack of essential funds. However, with recent foreign investments, the healthcare scenario is improving in the region. Hence the market in this region, though not large, is expected to grow in the future.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies

      2. 4.2.2 Innovations in Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in the number of Patent Expirations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Transitional Cell Bladder Cancer

      2. 5.1.2 Superficial Bladder Cancer

      3. 5.1.3 Invasive Bladder Cancer

      4. 5.1.4 Other Rare Types

    2. 5.2 By Diagnostics and Therapeutics

      1. 5.2.1 By Therapeutics

        1. 5.2.1.1 Chemotherapy

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Surgery

      2. 5.2.2 By Diagnostics

        1. 5.2.2.1 Cytoscopy

        2. 5.2.2.2 Biopsy

        3. 5.2.2.3 Urinalysis

        4. 5.2.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 Middle East and Africa

        1. 5.3.1.1 GCC

        2. 5.3.1.2 South Africa

        3. 5.3.1.3 Rest of Middle East and Africa

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc.

      2. 6.1.2 Bristol Myers Squibb

      3. 6.1.3 Eli Lilly and Co.

      4. 6.1.4 GlaxoSmithKline Plc.

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Johnson and Johnson

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sanofi S.A.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA Bladder Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The MEA Bladder Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 5.6% over the next 5 years.

Pfizer Inc., Johnson and Johnson, AstraZeneca Plc., Bristol Myers Squibb, Merck & Co., Inc. are the major companies operating in MEA Bladder Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!